To include your compound in the COVID-19 Resource Center, submit it here.

Sigilon finds partner in Lilly for T1D encapsulated cell therapy

Sigilon Therapeutics Inc. (Cambridge, Mass.) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to Sigilon's Type I diabetes program in a deal potentially worth

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE